Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo Parallel-controlled Phase III Clinical Trial on the Efficacy and Safety of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome (Intermingled Cold and Heat).

NCT06696261 is registered in ClinicalTrials.gov with Tasly Pharmaceutical Group Co., Ltd as lead sponsor.

NCT NCT06696261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06696261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo Parallel-controlled Phase III Clinical Trial on the Efficacy and Safety of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome (Intermingled Cold and Heat).
Lead sponsor
Tasly Pharmaceutical Group Co., Ltd
Phase
Phase 3
Overall status
Recruiting
Start date
February 27, 2025
Completion date
December 31, 2026
Enrollment
342 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

postprandial distress syndrome